This week and year to date, the increase of medical index was - 1.08% and - 23.25% respectively, and the excess return relative to Shanghai and Shenzhen 300 was - 1.01% and - 4.54% respectively; This week, the share prices of medical services, biological products, medical beauty and traditional Chinese medicine were relatively strong, while the share prices of chemical drugs, instruments and Commerce fell significantly; This week, the highest growth rate was Shanghai Yizhong Pharmaceutical Co.Ltd(688091) (+ 42.63%), Shandong Xinhua Pharmaceutical Company Limited(000756) (+ 41.36%), Hainan Shuangcheng Pharmaceuticals Co.Ltd(002693) (+ 39.11%), and the highest decline was Zhuhai Hokai Medical Instruments Co.Ltd(300273) (- 41.95%), Intco Medical Technology Co.Ltd(300677) (- 27.92%), Ji Yao Holding Group Co.Ltd(300108) . (- 26.26%). Performance characteristics of rise and fall: with the rebound of the market, the rise of the pharmaceutical sector is more obvious, but the decline of small market capitalization companies is greater; Consumer stocks with better than expected performance, such as Autek China Inc(300595) , Zhejiang Wolwo Bio-Pharmaceutical Co.Ltd(300357) , etc; Nucleic acid testing in Hangzhou and other places has been normalized, and the share prices of relevant service companies have a strong performance, among which the share prices of nucleic acid and antigen reagent companies have a short-term negative cashing trend.
The performance of CXO industry targets in 2021 and 2022q1 increased significantly, maintaining the high outlook of the industry. There are 18 A-shares 18 18 A shares 18 a 18 a 18 a 18 a 18 a 18 a 18 a 18 a 18 a 18 a 18 A a 18 A a 18 A a 18 A a 18 A a 18 A a 18 A a 18 A a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a 18 A a a 18 A a a a 18 A a a a 18 A a a a a CXO '' '' '' '' '' '' '' '' '' '' '' '' '' '' ''' \ , Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) , Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) , Shanghai Haoyuan Chemexpress Co.Ltd(688131) , Shanghai Medicilon Inc(688202) , Hitgen Inc(688222) , Heyuan biology, Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) ) the performance in 2021 is slightly better than the market expectation, and the performance in 2022q1 reflects the high prosperity of the industry. Therefore, we believe that the prosperity of CXO industry remains unchanged and has the value of equipment.
AstraZeneca's anti-CTLA-4 / PD-L1 antibody combination entered the priority review, and Baitai biological submitted the listing application for new indications of nituzumab injection: AstraZeneca announced that the biological product license application submitted by the company for developing CTLA-4 antibody tremelimumab was accepted by FDA, and will be reviewed through the priority review channel to treat unresectable hepatocellular carcinoma in combination with anti-PD-L1 antibody imfinzi; Baitai biological submitted and accepted the application for listing of new indications of nituzumab injection on April 25. Nituzumab is an anti EGFR humanized monoclonal antibody, which has previously been approved for the treatment of nasopharyngeal carcinoma in China.
Specific allocation ideas: 1) medical service fields: Aier Eye Hospital Group Co.Ltd(300015) , Topchoice Medical Co.Inc(600763) , haijiya medical, Ningbo Sanxing Medical Electric Co.Ltd(601567) , etc; 2) Medical and aesthetic fields: Imeik Technology Development Co.Ltd(300896) , Bloomage Biotechnology Corporation Limited(688363) , Huadong Medicine Co.Ltd(000963) , Shanghai Haohai Biological Technology Co.Ltd(688366) , etc; 3) Shanghai sector: Shanghai Pharmaceuticals Holding Co.Ltd(601607) , Tofflon Science And Technology Group Co.Ltd(300171) , Shanghai Microport Endovascular Medtech (Group) Co.Ltd(688016) , etc; 4) Generic CXO field: Baicheng pharmaceutical, focus on Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) etc; 5) Innovative drugs and industrial chain: Porton Pharma Solutions Ltd(300363) , Wuxi Apptec Co.Ltd(603259) , Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) , Asymchem Laboratories (Tianjin) Co.Ltd(002821) , etc; 6) Biotech innovative drugs: kangfang biology, Xinda biology, Yasheng medicine, etc; 7) API field: Jiangxi Synergy Pharmaceutical Co.Ltd(300636) , Apeloa Pharmaceutical Co.Ltd(000739) , Zhejiang Starry Pharmaceutical Co.Ltd(603520) , Zhejiang Tianyu Pharmaceutical Co.Ltd(300702) , etc; 8) Vaccine field: Chongqing Zhifei Biological Products Co.Ltd(300122) , Shenzhen Kangtai Biological Products Co.Ltd(300601) , Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) , etc; 9) Growth hormone field: Changchun High And New Technology Industries (Group) Inc(000661) , Anhui Anke Biotechnology (Group)Co.Ltd(300009) etc; 10) Blood products: Boya Bio-Pharmaceutical Group Co.Ltd(300294) , Beijing Tiantan Biological Products Corporation Limited(600161) etc; 11) Medical device field: Jiangsu Yuyue Medical Equipment And Supply Co.Ltd(002223) , Qingdao Novelbeam Technology Co.Ltd(688677) , Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) , etc; 12) Field of traditional Chinese medicine: Zhejiang Jolly Pharmaceutical Co.Ltd(300181) , Hubei Jumpcan Pharmaceutical Co.Ltd(600566) , Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) , etc.
Risk warning: the price reduction of drugs or consumables continues to exceed expectations; Covid-19 epidemic situation is repeated; The medical insurance policy was further tightened.
